BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
Cerexa expands portfolio of novel anti-infective therapies through in-licensing agreement with Meiji Seika Kaisha
News | 11. 01. 2006
Cerexa
Cerexa Inc. today announced it has expanded its portfolio of novel anti-infective therapies through an in-licensing agreement with Meiji Seika Kaisha Ltd.
